Equities

Jiangsu Bioperfectus Technologies Co Ltd

688399:SHH

Jiangsu Bioperfectus Technologies Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)81.50
  • Today's Change-2.57 / -3.06%
  • Shares traded705.14k
  • 1 Year change+48.83%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,4642,8071,910
Total Receivables, Net135636353
Total Inventory94236250
Prepaid expenses173024
Other current assets, total0.370.370.37
Total current assets2,7103,7092,539
Property, plant & equipment, net615734737
Goodwill, net------
Intangibles, net302727
Long term investments416254123
Note receivable - long term------
Other long term assets------
Total assets3,9064,8913,499
LIABILITIES
Accounts payable75433353
Accrued expenses90173154
Notes payable/short-term debt15889162
Current portion long-term debt/capital leases7.828.387.32
Other current liabilities, total33229179
Total current liabilities364933856
Total long term debt8.70116.90
Total debt174107177
Deferred income tax0.00163.53
Minority interest------
Other liabilities, total12915397
Total liabilities5011,113963
SHAREHOLDERS EQUITY
Common stock595959
Additional paid-in capital807806806
Retained earnings (accumulated deficit)2,5402,9141,672
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity3,4053,7782,536
Total liabilities & shareholders' equity3,9064,8913,499
Total common shares outstanding595959
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.